Iontophoresis as a possible therapy for digital ischaemia

Iontophoresis as a possible therapy for digital ischaemia - preliminary studies in patients with scleroderma spectrum disorders

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN84211155

Enrollment

Registered

2010-05-12

Start date

2006-09-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: Skin, Musculoskeletal

Interventions

Iontophoresis will be delivered over the whole finger. The iontophoresis dose will be 200 uA of 0.5% NaNP (diluted by volume in distilled water) for 5 mins, 4 times a day (but this will be reduced if

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. A diagnosis of SSc (or of another scleroderma-spectrum disorder) 2. Severe digital ischaemia 3. Digital ulceration severe enough to require hospitalisation for intravenous prostanoid therapy 4. Aged 18 - 80 years, either sex

Exclusion criteria

Exclusion criteria: 1. Aged less than 18 or greater than 80 years 2. Pregnancy

Design outcomes

Primary

Measure	Time frame
Increase in perfusion; one laser Doppler image will be taken before and after treatment on days 1, 2 and 5 where possible.	—

Secondary

Measure	Time frame
1. Modified Scleroderma Health Assessment Questionnaire (SHAQ); these will be filled out by patients at the start and end of the 5 day treatment period 2. Patient opinion, measured at the end of the 5 day treatment period	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026